Reuters logo
Federal appeals court rules Mylan can proceed with generic Angiomax
April 6, 2017 / 5:36 PM / 8 months ago

Federal appeals court rules Mylan can proceed with generic Angiomax

April 6 (Reuters) - A U.S. appeals court ruled that Mylan Inc’s proposed generic version of the blood thinner Angiomax would not infringe on patents held by The Medicines Company.

The U.S. Court of Appeals for the Federal Circuit reversed a decision by a federal judge in Illinois who ruled for The Medicines Company. (Reporting by Jan Wolfe)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below